A proven track record of value creation
We are a multinational pharmaceutical company with a local presence across North America and Canada, MENA and Europe, providing our customers with a broad range of generic, specialty and branded pharmaceutical products
Hikma released its financial results for the year ended 31 December 2025 on Thursday 26 February 2026.
Recent results
Full year 2025 results
Khalid Nabilsi, Deputy CEO, North America and Europe
Learn more about Hikma
Our purpose is to put better health within reach, every day
Read about our progress
Annual Report
Ensuring patients have access to the medicines they need is at the heart of everything we do. In 2025, we continued to invest in our people, capabilities, and infrastructure to strengthen our ability to deliver high-quality, affordable medicines across the communities we serve.
Newsroom
All news stories
Latest news
Featured
Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes
Press Release, Financial Results
- Hikma comments on Supreme Court of the United States’ unanimous decision in favour of Hikma Press Release, Corporate 04 June 2026 Hikma comments on Supreme Court of the United States’ unanimous decision in favour of Hikma
- Hikma Pharmaceuticals puts access to medicines at the heart of its sustainability strategy, reaching 222 million patients worldwide Press Release, Corporate 04 June 2026 Hikma Pharmaceuticals puts access to medicines at the heart of its sustainability strategy, reaching 222 million patients worldwide
- Hikma launches Tofacitinib oral solution in the US Press Release, Product 03 June 2026 Hikma launches Tofacitinib oral solution in the US
- Hikma Pharmaceuticals and Marius Pharmaceuticals announce licensing agreement for KYZATREX® (testosterone undecanoate) CIII capsules in Canada Press Release, Product 05 May 2026 Hikma Pharmaceuticals and Marius Pharmaceuticals announce licensing agreement for KYZATREX® (testosterone undecanoate) CIII capsules in Canada